Targacept News (NASDAQ:TRGT)
| Latest Targacept News Headlines | | Date | Time | Source | | | 05/31/2007 | 8:55AM | PRNUS | Targacept to Present at Bear Stearns Biotech Confab
WINSTON-SALEM, N.C., May 31 /PRNewswire-FirstCall/ -- Targacept, Inc. (NASDAQ:TRGT), a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR Therapeutics(TM), today announced that J. Donald deBethizy, Ph.D., President and Chief Executive Officer, will present at the Bear Stearns Biotech... More...>> |
| 05/09/2007 | 4:05PM | PRNUS | Targacept Reports First Quarter 2007 Financial Results
WINSTON-SALEM, N.C., May 9 /PRNewswire-FirstCall/ -- Targacept, Inc. (NASDAQ:TRGT), a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR Therapeutics(TM), today reported its financial results for the first quarter ended March 31, 2007.
(Logo: http://www.newscom.com/cgi-bin/prnh/20010517/CHTH002LOGO... More...>> |
| 03/22/2007 | 8:55AM | PRNUS | Targacept to Present at Upcoming Investor Conferences
WINSTON-SALEM, N.C., March 22 /PRNewswire-FirstCall/ -- Targacept, Inc. (NASDAQ:TRGT), a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR Therapeutics(TM), today announced that J. Donald deBethizy, Ph.D., President and Chief Executive Officer, will be presenting at three upcoming... More...>> |
| 02/22/2007 | 4:05PM | PRNUS | Targacept Reports Fourth Quarter and 2006 Financial Results
- Revenue Up Significantly and Cash Position Strengthened -
WINSTON-SALEM, N.C., Feb. 22 /PRNewswire-FirstCall/ -- Targacept, Inc. (NASDAQ:TRGT), a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR Therapeutics(TM), today reported its financial results for the fourth quarter and year... More...>> |
| 02/12/2007 | 8:55AM | PRNUS | Targacept to Report Fourth Quarter and Full Year 2006 Results on February 22, 2007
WINSTON-SALEM, N.C., Feb. 12 /PRNewswire-FirstCall/ -- Targacept, Inc. (NASDAQ:TRGT), a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR Therapeutics(TM), today announced that it will conduct a conference call and audio webcast at 5:00 p.m. ET on Thursday, February 22, 2007 following... More...>> |
| 02/05/2007 | 9:00AM | PRNUS | Targacept to Present at BIO CEO and Investor Conference
WINSTON-SALEM, N.C., Feb. 5 /PRNewswire-FirstCall/ -- Targacept, Inc. (NASDAQ:TRGT), a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR Therapeutics(TM), today announced that J. Donald deBethizy, Ph.D., President and Chief Executive Officer, will be presenting at the 9th Annual BIO... More...>> |
| 01/31/2007 | 9:00AM | PRNUS | Targacept to Expand Facilities at Piedmont Triad Research Park
WINSTON-SALEM, N.C., Jan 31 /PRNewswire-FirstCall/ -- The Piedmont Triad Research Park (PTRP), today announced plans for Targacept, Inc. (NASDAQ:TRGT) to expand its office and laboratory space at One Technology Place in the PTRP. Targacept currently occupies two floors of the building, a total of approximately 40,000... More...>> |
| 01/08/2007 | 8:55AM | PRNUS | Targacept Initiates Phase I Clinical Trial of TC-2216
WINSTON-SALEM, N.C., Jan. 8 /PRNewswire-FirstCall/ -- Targacept, Inc. (NASDAQ:TRGT), a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR Therapeutics(TM), today announced that it has initiated a Phase I clinical trial of TC-2216, its product candidate for the treatment of depression... More...>> |
| 01/03/2007 | 6:30AM | PRNUS | Donald P. Beeman Is Appointed Chairman of the Board of Directors at LigoCyte Pharmaceuticals, Inc.
BOZEMAN, Mont., Jan. 3 /PRNewswire/ -- LigoCyte Pharmaceuticals Inc. announces that its Board of Directors has appointed Donald P. Beeman as Chairman of the Board. Mr. Beeman has been the chief executive officer at LigoCyte since May of 2006. Mr. Beeman succeeds William G. Little who has served as the chairman since... More...>> |
| 12/27/2006 | 8:55AM | PRNUS | Targacept to Receive $20 Million Milestone Payment as AstraZeneca Plans to Continue Development of AZD3480 (TC-1734)
WINSTON-SALEM, N.C., Dec. 27 /PRNewswire-FirstCall/ -- Targacept, Inc. (NASDAQ:TRGT) today announced that AstraZeneca (NYSE:AZN) plans to continue development of AZD3480 (TC-1734) in Alzheimer's disease and cognitive deficits in schizophrenia. AstraZeneca's determination to continue development triggers a $20 million... More...>> |
| 12/19/2006 | 8:55AM | PRNUS | Targacept Begins Phase II Clinical Trial in Acute Post-Operative Pain
WINSTON-SALEM, N.C., Dec. 19 /PRNewswire-FirstCall/ -- Targacept, Inc. (NASDAQ:TRGT), a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR Therapeutics(TM), today announced that it has initiated a Phase II clinical trial of TC-2696, its product candidate for the treatment of acute... More...>> |
| 12/14/2006 | 6:30AM | PRNUS | LigoCyte Pharmaceuticals Announces the Addition of Dr. Donald deBethizy to Their Board of Directors
BOZEMAN, Mont., Dec. 14 /PRNewswire/ -- LigoCyte Pharmaceuticals Inc. announces that Dr. J. Donald deBethizy has joined the company's Board of Directors.
Dr. deBethizy has served as the president, CEO, and member of the board of directors at Targacept (NASDAQ:TRGT) since August, 2000 and as president and member of... More...>> |
| 12/04/2006 | 3:00PM | PRNUS | Targacept to Ring the NASDAQ Stock Market Closing Bell
WINSTON-SALEM, N.C., Dec. 4 /PRNewswire-FirstCall/ -- Targacept, Inc. (NASDAQ:TRGT), a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR Therapeutics(TM), announced today that J. Donald deBethizy, President and Chief Executive Officer, will ring the closing bell at The NASDAQ Stock... More...>> |
| 11/29/2006 | 8:55AM | PRNUS | Targacept to Host NNR Analyst Day in New York
WINSTON-SALEM, N.C., Nov. 29 /PRNewswire-FirstCall/ -- As previously announced, Targacept, Inc. (NASDAQ:TRGT), a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR Therapeutics(TM), will host a Neuronal Nicotinic Receptor (NNR) Analyst Day on Thursday, December 7, 2006 in New York... More...>> |
| 11/29/2006 | 8:55AM | PRNUS | Targacept to Host NNR Analyst Day in New York
WINSTON-SALEM, N.C., Nov. 29 /PRNewswire-FirstCall/ -- As previously announced, Targacept, Inc. (NASDAQ:TRGT), a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR Therapeutics(TM), will host a Neuronal Nicotinic Receptor (NNR) Analyst Day on Thursday, December 7, 2006 in New York... More...>> |
| 11/21/2006 | 8:55AM | PRNUS | Targacept to Present at Lazard and CIBC Investor Conferences
WINSTON-SALEM, N.C., Nov. 21 /PRNewswire-FirstCall/ -- Targacept, Inc. (NASDAQ:TRGT), a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR Therapeutics(TM), today announced that J. Donald deBethizy, Ph.D., President and Chief Executive Officer, will be presenting at two upcoming investor... More...>> |
| 11/09/2006 | 4:01PM | PRNUS | Targacept Reports Third Quarter 2006 Financial Results
- NNR Analyst Day Scheduled for December 7, 2006 -
WINSTON-SALEM, N.C., Nov. 9 /PRNewswire-FirstCall/ -- Targacept, Inc. (NASDAQ:TRGT), a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR Therapeutics(TM), today reported its financial results for the third quarter ended September... More...>> |
| 11/09/2006 | 8:55AM | PRNUS | Targacept Announces Positive Results of Phase II Clinical Trial in Major Depression
Top Line Data Suggest Potential of TRIDMAC(TM) in Non-Responsive Patients
WINSTON-SALEM, N.C., Nov. 9 /PRNewswire-FirstCall/ -- Targacept, Inc. (NASDAQ:TRGT) today reported positive results from a double blind, placebo controlled Phase II clinical trial of mecamylamine hydrochloride as an augmentation treatment for... More...>> |
| 11/02/2006 | 8:55AM | PRNUS | Targacept to Report Third Quarter Financial Results on November 9, 2006
WINSTON-SALEM, N.C., Nov. 2 /PRNewswire-FirstCall/ -- Targacept, Inc. (NASDAQ:TRGT), today announced that the company will conduct a conference call and an audio webcast at 5:00 p.m. ET on Thursday, November 9, 2006 following the after-market release of its unaudited financial results for the third quarter ended September... More...>> |
| 10/25/2006 | 8:55AM | PRNUS | Targacept to Present at Upcoming Investor Conferences
J. Donald deBethizy Scheduled to Present at C.E. Unterberg, Towbin Life Sciences Conference and CIBC World Markets Annual Healthcare Conference
WINSTON-SALEM, N.C., Oct. 25 /PRNewswire-FirstCall/ -- Targacept, Inc. (NASDAQ:TRGT), a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR... More...>> |
|
|
|